Susquehanna International Group’s CG Oncology CGON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.75M Buy
+25,803
New +$1.46M ﹤0.01% 6488
2025
Q3
Sell
-93,793
Closed -$2.73M 12530
2025
Q2
$2.44M Buy
93,793
+11,808
+14% +$285K ﹤0.01% 5376
2025
Q1
$2.01M Buy
81,985
+44,316
+118% +$1.25M ﹤0.01% 5536
2024
Q4
$1.08M Buy
37,669
+24,676
+190% +$844K ﹤0.01% 6755
2024
Q3
$490K Buy
+12,993
New +$455K ﹤0.01% 8508
2024
Q2
Sell
-11,149
Closed -$386K 12125
2024
Q1
$489K Buy
+11,149
New +$455K ﹤0.01% 8569

Other funds holding CGON

Susquehanna International Group's CGON Position: Q1 2026 in Review

Susquehanna International Group opened a new position in CG Oncology (CGON) in Q1 2026: 25,803 shares worth $1.75M. The stake represents ﹤0.01% of the portfolio and ranks #6488 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in CGON as recently as Q2 2025.

Susquehanna International Group first reported a position in CGON in Q1 2024 and has held it in 6 quarters since. The position peaked at $2.44M in Q2 2025. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Susquehanna International Group held 25,803 shares of CG Oncology worth $1.75M as of Q1 2026.
  • CG Oncology was a new Susquehanna International Group position in Q1 2026.
  • CG Oncology made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6488 holding.
  • Susquehanna International Group first reported a position in CG Oncology in Q1 2024 and has held it in 6 quarters since.
  • Susquehanna International Group's CG Oncology position peaked at $2.44M in Q2 2025.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.